What We Have Learned about Autism Spectrum Disorder from Valproic Acid

Area of Science:

• Neuroscience
• Developmental Biology
• Epidemiology

Background:

• Valproic acid (VPA) is an anticonvulsant medication with known teratogenic effects.
• Recent epidemiological studies suggest a correlation between prenatal VPA exposure and neurodevelopmental disorders, particularly autism spectrum disorder (ASD).
• Animal models utilizing VPA are increasingly employed to study ASD pathogenesis.

Purpose of the Study:

• To review and synthesize epidemiological evidence linking prenatal VPA exposure to ASD.
• To discuss key neurobiological mechanisms, including early brain overgrowth and network hyperexcitability, implicated in VPA-induced ASD.
• To enhance the understanding of how VPA affects early neurological development and its relevance to ASD.

Main Methods:

• Focused review of epidemiological investigations.
• Analysis of animal research literature on VPA as an ASD model.
• Synthesis of neurobiological findings related to VPA and ASD.

Main Results:

• Epidemiological studies indicate a significant risk of neurodevelopmental disorders, including ASD, in children exposed to VPA in utero.
• Neurobiological findings in VPA models point to accelerated brain overgrowth and hyperexcitable neural networks as critical factors.
• These findings provide a mechanistic link between VPA exposure and ASD phenotypes.

Conclusions:

• Prenatal exposure to valproic acid is associated with an increased risk of autism spectrum disorder.
• Early brain overgrowth and altered neural network excitability are crucial neurobiological consequences of VPA exposure relevant to ASD.
• Understanding VPA's impact on early neurological development offers insights into the etiology of ASD.